Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07093489

Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)

Sponsor: International Vaccine Institute

View on ClinicalTrials.gov

Summary

This is a health facility-based prospective test-negative (TND) case-control study to evaluate vaccine effectiveness and active safety monitoring (cohort event monitoring), and passive surveillance for evaluation of the safety of the LC16m8 mpox vaccine in individuals aged one year and older in the DRC. This study aims to assess the LC16m8 vaccine effectiveness and safety. The following activities will be carried out: * Community engagement * Enhanced health facility-based mpox disease surveillance * Vaccination using the LC16m8 vaccine * Safety monitoring following immunization * LC16m8 Vaccine effectiveness evaluation using a TND Study Hypothesis: The LC16m8 vaccine, administered as pre-exposure prophylaxis, confers greater than 70% protection against symptomatic mpox disease among adults and children in the DRC.

Official title: Evaluation of the Effectiveness and Safety of the LC16m8 Mpox Vaccine in Individuals Aged One Year and Older in the Democratic Republic of Congo (DRC)

Key Details

Gender

All

Age Range

1 Year - Any

Study Type

OBSERVATIONAL

Enrollment

11990

Start Date

2025-09-30

Completion Date

2027-12-31

Last Updated

2025-09-15

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

LC16m8

LC16m8 vaccine will be offered to all individuals aged \>1 year and meet the inclusion criteria within the catchment population. This will be done in line with the DRC government's LC16m8 vaccine roll out plan.

Locations (1)

The Institut National de la Recherche Biomédicale (INRB)

Kinshasa, Democratic Republic of the Congo